Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]
From General Health Awareness to Specialized Risk Understanding
If you or a loved one is taking Tysabri, you may have heard about the risk of progressive multifocal leukoencephalopathy (PML). This rare but serious brain infection can occur in patients treated with Tysabri, especially those with certain risk factors. Building on decades of public health communication that has empowered individuals to make informed decisions, this page provides clear, factual information about PML risk, symptoms, and monitoring—so you can have an informed conversation with your healthcare provider.
Tysabri and the Risk of Progressive Multifocal Leukoencephalopathy
Tysabri (natalizumab) is a monoclonal antibody used to treat multiple sclerosis and Crohn's disease. Its use carries a well-documented risk of Progressive Multifocal Leukoencephalopathy (PML), a severe opportunistic viral infection of the brain caused by the JC virus (JCV). PML typically occurs only in immunocompromised individuals and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The U.S. Food and Drug Administration (FDA) has mandated a boxed warning for Tysabri, highlighting this risk and requiring that healthcare professionals monitor patients for any new signs or symptoms suggestive of PML, with immediate withholding of dosing at the first indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The clinical presentation of PML is characterized by progressive neurological deficits, including cognitive impairment, motor weakness, and visual disturbances, which can be mistaken for multiple sclerosis relapses. Diagnosis relies on brain imaging, typically showing multifocal demyelinating lesions, and detection of JCV DNA in cerebrospinal fluid. A retrospective national cohort study of 456 PML cases observed between 1987 and 2024 described demographic, clinical, radiological, and laboratory characteristics, noting that PML is a severe demyelinating disease affecting immunocompromised individuals (https://pubmed.ncbi.nlm.nih.gov/40922664/). In Tysabri-treated patients, PML has been documented in clinical trials: two cases occurred among 1,869 multiple sclerosis patients treated for a median of 120 weeks, and one case occurred after eight doses in a Crohn's disease patient (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Mechanism and Risk Factors for PML in Tysabri Patients
The mechanistic pathway linking Tysabri to PML involves its pharmacological action. Tysabri binds to alpha-4 integrins on the surface of immune cells, preventing their migration across the blood-brain barrier. This reduces inflammation in the central nervous system but also impairs immune surveillance, allowing latent JCV to reactivate and cause PML. Three risk factors for PML in Tysabri-treated patients have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating and continuing treatment, balancing the expected benefit against the risk of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The adequacy of warnings regarding Tysabri and PML is a critical risk anchor. The FDA boxed warning explicitly states that Tysabri increases the risk of PML and that it usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The warning also mandates that Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program, which aims to ensure that patients are monitored for PML symptoms (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, questions may arise about whether patients and healthcare providers fully understand the magnitude of risk, particularly regarding the cumulative effect of treatment duration and prior immunosuppressant use. The label notes that patients who are anti-JCV antibody positive have a higher risk for developing PML, and that longer treatment duration, especially beyond two years, increases risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these warnings, PML cases continue to occur, raising concerns about the effectiveness of risk communication and monitoring.
Legal Considerations for Tysabri-Related PML Cases
For patients affected by PML, attorney-related considerations are important. The timeline between Tysabri exposure and documented harm can vary. In clinical trials, PML occurred after a median of 120 weeks of treatment in multiple sclerosis patients and after eight doses in a Crohn's disease patient (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This variability underscores the need for careful documentation of treatment duration and any symptoms that may indicate PML. Patients who develop PML may face severe disability or death, and legal action may be considered if there is evidence that warnings were inadequate or that monitoring was insufficient. Attorneys specializing in Tysabri-related PML cases can help affected individuals navigate the complexities of medical malpractice or product liability claims, focusing on whether the risks were properly communicated and whether appropriate steps were taken to prevent harm. In summary, Tysabri is associated with a significant risk of PML, a severe and often fatal brain infection. The FDA boxed warning provides clear guidance on risk factors and monitoring, but the occurrence of PML despite these measures highlights ongoing challenges. Patients and healthcare providers must remain vigilant, and those affected by PML may benefit from legal counsel to explore their options.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
What is Tysabri and what is it used for?
Tysabri (natalizumab) is a monoclonal antibody used to treat multiple sclerosis and Crohn's disease. It works by binding to alpha-4 integrins on immune cells, preventing their migration into the central nervous system, thereby reducing inflammation. However, this mechanism also increases the risk of Progressive Multifocal Leukoencephalopathy (PML), a severe brain infection caused by the JC virus.
What are the risk factors for developing PML while on Tysabri?
Three main risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants. Patients who are anti-JCV antibody positive have a higher risk, and the risk increases with cumulative treatment duration. These factors should be considered when initiating and continuing Tysabri therapy.
What legal options are available for individuals who developed PML after taking Tysabri?
Individuals who developed PML after Tysabri exposure may consider legal action if there is evidence that warnings were inadequate or monitoring was insufficient. Attorneys specializing in Tysabri-related PML cases can help navigate medical malpractice or product liability claims, focusing on risk communication and adherence to monitoring protocols.
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Community Resource & Benefit Desk
Request archival records or inquire about member-exclusive transition and benefit programs.
Free Case & Eligibility Review
Individuals with documented archive exposure and a related diagnosis may request an independent, no-cost eligibility review.